HIV‐1 Viral Escape in Cerebrospinal Fluid of Subjects on Suppressive Antiretroviral Treatment
Open Access
- 15 December 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 202 (12), 1819-1825
- https://doi.org/10.1086/657342
Abstract
Background. Occasional cases of viral escape in cerebrospinal fluid (CSF) despite suppression of plasma human immunodeficiency virus type 1 (HIV-1) RNA have been reported. We investigated CSF viral escape in subjects treated with commonly used antiretroviral therapy regimens in relation to intrathecal immune activation and central nervous system penetration effectiveness (CPE) rank. Methods. Sixty-nine neurologically asymptomatic subjects treated with antiretroviral therapy >6 months and plasma HIV-1 RNA Results. Seven (10%) of the 69 subjects had detectable CSF HIV-1 RNA, in median 121 copies/mL (interquartile range, 54–213 copies/mL). Subjects with detectable CSF virus had significantly higher CSF neopterin and longer duration of treatment. Previous treatment interruptions were more common in subjects with CSF escape. Central nervous system penetration effectiveness rank was not a significant predictor of detectable CSF virus or CSF neopterin levels. Conclusions. Viral escape in CSF is more common than previously reported, suggesting that low-grade central nervous system infection may continue in treated patients. Although these findings need extension in longitudinal studies, they suggest the utility of monitoring CSF responses, as new treatment combinations and strategies modify clinical practice.Keywords
This publication has 26 references indexed in Scilit:
- Therapy Failure following Selection of Enfuvirtide‐Resistant HIV‐1 in Cerebrospinal FluidClinical Infectious Diseases, 2010
- Detectable cerebrospinal fluid HIV RNA with associated neurological deficits, despite suppression of HIV replication in the plasma compartmentAIDS, 2009
- Compartmentalized Human Immunodeficiency Virus Type 1 Originates from Long-Lived Cells in Some Subjects with HIV-1–Associated DementiaPLoS Pathogens, 2009
- Treatment of HIV infection: Swedish recommendations 2009Scandinavian Journal of Infectious Diseases, 2009
- Antiretroviral Treatment Effect on Immune Activation Reduces Cerebrospinal Fluid HIV-1 InfectionJAIDS Journal of Acquired Immune Deficiency Syndromes, 2008
- Persistent Intrathecal Immune Activation in HIV-1-Infected Individuals on Antiretroviral TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2008
- Validation of the CNS Penetration-Effectiveness Rank for Quantifying Antiretroviral Penetration Into the Central Nervous SystemArchives of Neurology, 2008
- Updated research nosology for HIV-associated neurocognitive disordersNeurology, 2007
- Treatment Benefit on Cerebrospinal Fluid HIV‐1 Levels in the Setting of Systemic Virological Suppression and FailureThe Journal of Infectious Diseases, 2006
- Independent Evolution of Human Immunodeficiency Virus (HIV) Drug Resistance Mutations in Diverse Areas of the Brain in HIV-Infected Patients, with and without Dementia, on Antiretroviral TreatmentJournal of Virology, 2004